Epidermal growth factor receptor regulates β-catenin location, stability, and transcriptional activity in oral cancer

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Lee, Chien Hsing ^a,b   Hung, Hsing Wen ^a   Hung, Pei Hsin ^a   Shieh, Yi Shing ^a,b  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; BETA CATENIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; HISTONE DEACETYLASE 1; UVOMORULIN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; HISTONE;

ARTICLE; CANCER CELL CULTURE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; FEMALE; GENE CONTROL; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUTH CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; TRANSCRIPTION INITIATION; CELL FRACTIONATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MOUTH TUMOR; MUTATION; PATHOLOGY; PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

BETA CATENIN; CELL LINE, TUMOR; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN IMMUNOPRECIPITATION; CYCLIN D1; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOGEN SYNTHASE KINASE 3; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; MOUTH NEOPLASMS; MUTATION; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STABILITY; PROTEIN TRANSPORT; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SUBCELLULAR FRACTIONS; TRANSCRIPTION, GENETIC;

EID: 77952302757     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-64     Document Type: Article

References (53)

1. Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004, 303:1483-1487. 10.1126/science.1094291, 15001769.
2. Kishida S, Yamamoto H, Ikeda S, Kishida M, Sakamoto I, Koyama S, Kikuchi A. Axin, a negative regulator of the wnt signaling pathway, directly interacts with adenomatous polyposis coli and regulates the stabilization of beta-catenin. J Biol Chem 1998, 273:10823-10826. 10.1074/jbc.273.18.10823, 9556553.
3. Jankowski JA, Bruton R, Shepherd N, Sanders DS. Cadherin and catenin biology represent a global mechanism for epithelial cancer progression. Mol Pathol 1997, 50:289-290. 10.1136/mp.50.6.289, 379661, 9536277.
4. Barker N, Morin PJ, Clevers H. The Yin-Yang of TCF/beta-catenin signaling. Adv Cancer Res 2000, 77:1-24. full_text, 10549354.
5. Mareel MM, Behrens J, Birchmeier W, De Bruyne GK, Vleminckx K, Hoogewijs A, Fiers WC, Van Roy FM. Down-regulation of E-cadherin expression in Madin Darby canine kidney (MDCK) cells inside tumors of nude mice. Int J Cancer 1991, 47:922-928. 10.1002/ijc.2910470623, 2010235.
6. Clevers H, Wetering M. TCF/LEF factors earn their wings. Trends Genet 1997, 13:485-489. 10.1016/S0168-9525(97)01305-X, 9433138.
7. Aoki M, Hecht A, Kruse U, Kemler R, Vogt PK. Nuclear endpoint of Wnt signaling: neoplastic transformation induced by transactivating lymphoid-enhancing factor 1. Proc Natl Acad Sci USA 1999, 96:139-144. 10.1073/pnas.96.1.139, 15106, 9874785.
8. Odajima T, Sasaki Y, Tanaka N, Kato-Mori Y, Asanuma H, Ikeda T, Satoh M, Hiratsuka H, Tokino T, Sawada N. Abnormal beta-catenin expression in oral cancer with no gene mutation: correlation with expression of cyclin D1 and epidermal growth factor receptor, Ki-67 labeling index, and clinicopathological features. Hum Pathol 2005, 36:234-241. 10.1016/j.humpath.2004.12.009, 15791567.
9. Shieh YS, Chang LC, Chiu KC, Wu CW, Lee HS. Cadherin and catenin expression in mucoepidermoid carcinoma: correlation with histopathologic grade, clinical stage, and patient outcome. J Oral Pathol Med 2003, 32:297-304.
10. Miyoshi Y, Iwao K, Nagasawa Y, Aihara T, Sasaki Y, Imaoka S, Murata M, Shimano T, Nakamura Y. Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res 1998, 58:2524-2527.
11. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW. Identification of c-MYC as a target of the APC pathway. Science 1998, 281:1509-1512. 10.1126/science.281.5382.1509, 9727977.
12. Iwao K, Nakamori S, Kameyama M, Imaoka S, Kinoshita M, Fukui T, Ishiguro S, Nakamura Y, Miyoshi Y. Activation of the beta-catenin gene by interstitial deletions involving exon 3 in primary colorectal carcinomas without adenomatous polyposis coli mutations. Cancer Res 1998, 58:1021-1026.
13. Miyoshi Y, Iwao K, Nawa G, Yoshikawa H, Ochi T, Nakamura Y. Frequent mutations in the beta-catenin gene in desmoid tumors from patients without familial adenomatous polyposis. Oncol Res 1998, 10:591-594.
14. Chan EF, Gat U, McNiff JM, Fuchs E. A common human skin tumour is caused by activating mutations in beta-catenin. Nat Genet 1999, 21:410-413. 10.1038/7747, 10192393.
15. Garcia-Rostan G, Tallini G, Herrero A, D'Aquila TG, Carcangiu ML, Rimm DL. Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. Cancer Res 1999, 59:1811-1815.
16. Ashihara K, Saito T, Mizumoto H, Nishimura M, Tanaka R, Kudo R. Mutation of beta-catenin gene in endometrial cancer but not in associated hyperplasia. Med Electron Microsc 2002, 35:9-15. 10.1007/s007950200001, 12111402.
17. de La Coste A, Romagnolo B, Billuart P, Renard CA, Buendia MA, Soubrane O, Fabre M, Chelly J, Beldjord C, Kahn A, Perret C. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 1998, 95:8847-8851. 10.1073/pnas.95.15.8847, 21165, 9671767.
18. Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki T, Kawasoe T, Ishiguro H, Fujita M, Tokino T, Sasaki Y, Imaoka S, Murata M, Shimano T, Yamaoka Y, Nakamura Y. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 2000, 24:245-250. 10.1038/73448, 10700176.
19. Ihara A, Koizumi H, Hashizume R, Uchikoshi T. Expression of epithelial cadherin and alpha- and beta-catenins in nontumoral livers and hepatocellular carcinomas. Hepatology 1996, 23:1441-1447.
20. Brembeck FH, Rosario M, Birchmeier W. Balancing cell adhesion and Wnt signaling, the key role of beta-catenin. Curr Opin Genet Dev 2006, 16:51-59. 10.1016/j.gde.2005.12.007, 16377174.
21. Lu Z, Ghosh S, Wang Z, Hunter T. Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell 2003, 4:499-515. 10.1016/S1535-6108(03)00304-0, 14706341.
22. Forastiere AA, Burtness BA. Epidermal growth factor receptor inhibition in head and neck cancer: more insights, but more questions. J Clin Oncol 2007, 25:2152-2155. 10.1200/JCO.2007.10.9017, 17538157.
23. Lo HW, Xia W, Wei Y, Ali-Seyed M, Huang SF, Hung MC. Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res 2005, 65:338-348.
24. Gordon MD, Nusse R. Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem 2006, 281:22429-22433. 10.1074/jbc.R600015200, 16793760.
25. Lilien J, Balsamo J. The regulation of cadherin-mediated adhesion by tyrosine phosphorylation/dephosphorylation of beta-catenin. Curr Opin Cell Biol 2005, 17:459-465. 10.1016/j.ceb.2005.08.009, 16099633.
26. Willert K, Jones KA. Wnt signaling: Is the party in the nucleus?. Genes Dev 2006, 20:1394-1404. 10.1101/gad.1424006, 16751178.
27. Hoschuetzky H, Aberle H, Kemler R. Beta-catenin mediates the interaction of the cadherin-catenin complex with epidermal growth factor receptor. J Cell Biol 1994, 127:1375-1380. 10.1083/jcb.127.5.1375, 2120252, 7962096.
28. Moon HS, Choi EA, Park HY, Choi JY, Chung HW, Kim JI, Park WI. Expression and tyrosine phosphorylation of E-cadherin, beta- and gamma-catenin, and epidermal growth factor receptor in cervical cancer cells. Gynecol Oncol 2001, 81:355-359. 10.1006/gyno.2001.6163, 11371122.
29. Liu SY, Chang LC, Pan LF, Hung YJ, Lee CH, Shieh YS. Clinicopathologic significance of tumor cell-lined vessel and microenvironment in oral squamous cell carcinoma. Oral Oncol 2007, 44:277-285. 10.1016/j.oraloncology.2007.02.007, 17475541.
30. Ni CY, Murphy MP, Golde TE, Carpenter G. gamma-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 2001, 294:2179-2181. 10.1126/science.1065412, 11679632.
31. Prall F, Weirich V, Ostwald C. Phenotypes of invasion in sporadic colorectal carcinomaa related to aberrations of the adenomatous polyposis coli (APC) gene. Histopathology 2007, 50:218-230.
32. Ilyas M. Wnt signalling and the mechanistic basis of tumour development. J Pathol 2005, 205:130-144. 10.1002/path.1692, 15641015.
33. Kajiguchi T, Lee S, Lee MJ, Trepel JB, Neckers L. KIT regulates tyrosine phosphorylation and nuclear localization of beta-catenin in mast cell leukemia. Leuk Res 2008, 32:761-770. 10.1016/j.leukres.2007.08.023, 2682210, 17949810.
34. Camp ER, Yang A, Gray MJ, Fan F, Hamilton SR, Evans DB, Hooper AT, Pereira DS, Hicklin DJ, Ellis LM. Tyrosine kinase receptor RON in human pancreatic cancer: expression, function, and validation as a target. Cancer 2007, 109:1030-1039. 10.1002/cncr.22490, 17311308.
35. Zinser GM, Leonis MA, Toney K, Pathrose P, Thobe M, Kader SA, Peace BE, Beauman SR, Collins MH, Waltz SE. Mammary-specific Ron receptor overexpression induces highly metastatic mammary tumors associated with beta-catenin activation. Cancer Res 2006, 66:11967-11974. 10.1158/0008-5472.CAN-06-2473, 17178895.
36. Coluccia AM, Vacca A, Duñach M, Mologni L, Redaelli S, Bustos VH, Benati D, Pinna LA, Gambacorti-Passerini C. Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. EMBO J 2007, 26:1456-1466. 10.1038/sj.emboj.7601485, 1817619, 17318191.
37. Hamaguchi M, Matsuyoshi N, Ohnishi Y, Gotoh B, Takeichi M, Nagai Y. p60v-src causes tyrosine phosphorylation and inactivation of the N-cadherin-catenin cell adhesion system. EMBO J 1993, 12:307-314. 413207, 8381351.
38. Shibata T, Gotoh M, Ochiai A, Hirohashi S. Association of plakoglobin with APC, a tumor suppressor gene product, and its regulation by tyrosine phosphorylation. Biochem Biophys Res Commun 1994, 203:519-522. 10.1006/bbrc.1994.2213, 8074697.
39. Hu P, O'Keefe EJ, Rubenstein DS. Tyrosine phosphorylation of human keratinocyte beta-catenin and plakoglobin reversibly regulates their binding to E-cadherin and alpha-catenin. J Invest Dermatol 2001, 117:1059-1067. 10.1046/j.0022-202x.2001.01523.x, 11710913.
40. Kurdistani SK, Grunstein M. Histone acetylation and deacetylation in yeast. Nat Rev Mol Cell Biol 2003, 4:276-284. 10.1038/nrm1075, 12671650.
41. Jenuwein T, Allis CD. Translating the histone code. Science 2001, 293:1074-1080. 10.1126/science.1063127, 11498575.
42. Huber AH, Weis WI. The structure of the beta-catenin/E-cadherin complex and the molecular basis of diverse ligand recognition by beta-catenin. Cell 2001, 105:391-402. 10.1016/S0092-8674(01)00330-0, 11348595.
43. Cavallo RA, Cox RT, Moline MM, Roose J, Polevoy GA, Clevers H, Peifer M, Bejsovec A. Drosophila Tcf and Groucho interact to repress Wingless signalling activity. Nature 1998, 395:604-608. 10.1038/26982, 9783586.
44. Brantjes H, Roose J, Wetering M, Clevers H. All Tcf HMG box transcription factors interact with Groucho-related co-repressors. Nucleic Acids Res 2001, 29:1410-1419. 10.1093/nar/29.7.1410, 31284, 11266540.
45. Daniels DL, Weis WI. Beta-catenin directly displaces Groucho/TLE repressors from Tcf/Lef in Wnt-mediated transcription activation. Nat Struct Mol Biol 2005, 12:364-371. 10.1038/nsmb912, 15768032.
46. Bannister AJ, Kouzarides T. Histone methylation: recognizing the methyl mark. Methods Enzymol 2004, 376:269-288. full_text, 14975312.
47. Yochum GS, Cleland R, Goodman RH. A genome-wide screen for beta-catenin binding sites identifies a downstream enhancer element that controls c-Myc gene expression. Moll Cell Biol 2008, 28:7368-7379.
48. Pukkila MJ, Virtaniemi JA, Kumpulainen EJ, Pirinen RT, Johansson RT, Valtonen HJ, Juhola MT, Kosma VM. Nuclear beta catenin expression is related to unfavourable outcome in oropharyngeal and hypopharyngeal squamous cell carcinoma. J Clin Pathol 2001, 54:42-47. 10.1136/jcp.54.1.42, 1731271, 11271788.
49. Gasparoni A, Chaves A, Fonzi L, Johnson GK, Schneider GB, Squier CA. Subcellular localization of beta-catenin in malignant cell lines and squamous cell carcinomas of the oral cavity. J Oral Pathol Med 2002, 31:385-394. 10.1034/j.1600-0714.2002.00108.x, 12165056.
50. Klein EA, Assoian RK. Transcriptional regulation of the cyclin D1 gene at a glance. J Cell Sci 2008, 121:3853-3857. 10.1242/jcs.039131, 19020303.
51. Tashiro E, Tsuchiya A, Imoto M. Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression. Cancer Sci 2007, 98:629-635. 10.1111/j.1349-7006.2007.00449.x, 17359287.
52. Akervall JA, Michalides RJ, Mineta H, Balm A, Borg A, Dictor MR, Jin Y, Loftus B, Mertens F, Wennerberg JP. Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression. Cancer 1997, 79:380-389. 10.1002/(SICI)1097-0142(19970115)79:2<380::AID-CNCR22>3.0.CO;2-W, 9010112.
53. Bellacosa A, Almadori G, Cavallo S, Cadoni G, Galli J, Ferrandina G, Scambia G, Neri G. Cyclin D1 gene amplification in human laryngeal squamous cell carcinomas: prognostic significance and clinical implications. Clin Cancer Res 1996, 2:175-180.